Immunomodulatory Effects of Volatile Anesthetic Sevoflurane on Cardiomyocytes after Coronary Artery Bypass Grafting: Insights from Bioinformatics Analysis
Sevoflurane Modulates Immune-Related Gene Expression after CABG
Abstract
Volatile anesthetics, particularly sevoflurane, have demonstrated cardioprotective properties during cardiac surgery. However, their immunomodulatory mechanisms at the molecular level remain unclear. Given the close relationship between cardiac injury and immune responses, understanding how anesthetic agents influence immune-related pathways may provide new insights into perioperative myocardial protection.
This study aimed to explore the immunological and molecular mechanisms underlying the effects of sevoflurane anesthesia on cardiomyocytes in patients undergoing coronary artery bypass grafting (CABG).
Gene expression data (GSE4386) from myocardial tissues of CABG patients anesthetized with sevoflurane or propofol were analyzed. Differentially expressed genes (DEGs) were identified using R software, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Protein–protein interaction networks were constructed to identify key immune-associated hub genes. A total of 211 DEGs were identified. Functional enrichment revealed that these genes were predominantly associated with immune and inflammatory processes, including leukocyte activation, cytokine–cytokine receptor interaction, neutrophil extracellular trap formation, and chemokine signaling pathways. Hub genes such as ITGAM, PTPRC, TYROBP, TLR2, and TLR4 were identified as central immune regulators potentially mediating the cardioprotective and immunomodulatory effects of sevoflurane.
Sevoflurane anesthesia may confer myocardial protection after CABG by modulating immune-related signaling pathways and inflammatory gene expression. These findings highlight the immunoregulatory potential of volatile anesthetics, providing novel perspectives for immune-targeted strategies in perioperative cardiac management.
2. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology. 2004;100(3):707-21.
3. Bland JH, Lowenstein E. Halothane-induced decrease in experimental myocardial ischemia in the non-failing canine heart. Anesthesiology. 1976;45(3):287-93.
4. Hannan EL, Zhong Y, Lahey SJ, Culliford AT, Gold JP, Smith CR, et al. 30-day readmissions after coronary artery bypass graft surgery in New York State. Jacc-Cardiovasc Inte. 2011;4(5):569-76.
5. Li Z, Armstrong EJ, Parker JP, Danielsen B, Romano PS. Hospital variation in readmission after coronary artery bypass surgery in California. Circ Cardiovasc Qual Outcomes. 2012;5(5):729-37.
6. Fox JP, Suter LG, Wang K, Wang Y, Krumholz HM, Ross JS. Hospital-based, acute care use among patients within 30 days of discharge after coronary artery bypass surgery. Ann Thorac Surg. 2013;96(1):96-104.
7. Shahian DM, O'Brien SM, Normand SL, Peterson ED, Edwards FH. Association of hospital coronary artery bypass volume with processes of care, mortality, morbidity, and the Society of Thoracic Surgeons composite quality score. J Thorac Cardiov Sur. 2010;139(2):273-82.
8. Ashikhmina EA, Schaff HV, Sinak LJ, Li Z, Dearani JA, Suri RM, et al. Pericardial effusion after cardiac surgery: risk factors, patient profiles, and contemporary management. Ann Thorac Surg. 2010;89(1):112-8.
9. Leiva EH, Carreno M, Bucheli FR, Bonfanti AC, Umana JP, Dennis RJ. Factors associated with delayed cardiac tamponade after cardiac surgery. Ann Card Anaesth. 2018;21(2):158-66.
10. Hirji SA, Lee J, Kaneko T. Current Readings: An Update on Prevention and Management of Atrial Fibrillation Post Cardiac Surgery. Semin Thorac Cardiov. 2018;30(3):256-61.
11. Khan J, Khan N, Loisa E, Sutinen J, Laurikka J. Increasing Occurrence of Postoperative Atrial Fibrillation in Contemporary Cardiac Surgery. J Cardiothor Vasc an. 2016;30(5):1302-7.
12. Schlack W, Preckel B, Stunneck D, Thamer V. Effects of halothane, enflurane, isoflurane, sevoflurane and desflurane on myocardial reperfusion injury in the isolated rat heart. Brit J Anaesth. 1998;81(6):913-9.
13. Ebel D, Preckel B, You A, Mullenheim J, Schlack W, Thamer V. Cardioprotection by sevoflurane against reperfusion injury after cardioplegic arrest in the rat is independent of three types of cardioplegia. Brit J Anaesth. 2002;88(6):828-35.
14. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasche P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation. 1999;100(19 Suppl):II340-4.
15. De Hert SG, Ten BP, Mertens E, Van Sommeren EW, De Blier IG, Stockman BA, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology. 2002;97(1):42-9.
16. De Hert SG, Cromheecke S, Ten BP, Mertens E, De Blier IG, Stockman BA, et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology. 2003;99(2):314-23.
17. Kersten JR, Lowe D, Hettrick DA, Pagel PS, Gross GJ, Warltier DC. Glyburide, a KATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium. Anesth Analg. 1996;83(1):27-33.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Coronary artery bypass grafting Cytokine signaling Gene expression Immunomodulation Sevoflurane TLR pathway | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
